Multicentric Ga-PSMA PET radiomics for treatment response assessment of Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.

Journal: Frontiers in nuclear medicine
Published Date: Sep 14, 2023

Abstract

OBJECTIVE: The treatment with Lutetium PSMA (Lu-PSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC) has recently been approved by the FDA and EMA. Since treatment success is highly variable between patients, the prediction of treatment response and identification of short- and long-term survivors after treatment could help tailor mCRPC diagnosis and treatment accordingly. The aim of this study is to investigate the value of radiomic parameters extracted from pretreatment Ga-PSMA PET images for the prediction of treatment response.

Authors

  • Robin Gutsche
    Institute of Neuroscience and Medicine (INM-4), Forschungszentrum Juelich, Juelich, Germany.
  • Gizem Gülmüs
    RWTH Aachen University, Aachen, Germany.
  • Felix M Mottaghy
    Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.
  • Florian Gärtner
    Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
  • Markus Essler
    Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
  • Dirk von Mallek
    Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.
  • Hojjat Ahmadzadehfar
    Department of Nuclear Medicine, Klinikum Westphalen, Dortmund, Germany.
  • Philipp Lohmann
    Institute of Neuroscience and Medicine (INM-4), Forschungszentrum Juelich, Juelich, Germany.
  • Alexander Heinzel
    Institute of Neuroscience and Medicine (INM-4), Forschungszentrum Juelich, Juelich, Germany.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals